 |
|  |
Jul-23-19 | Upgrade |
JP Morgan |
Neutral → Overweight |
$8 → $16 |
|
Jul-05-19 | Reiterated |
Robert W. Baird |
Outperform |
$15 → $25 |
|
Jul-05-19 | Reiterated |
H.C. Wainwright |
Buy |
$29 → $32 |
|
Mar-01-19 | Downgrade |
JP Morgan |
Overweight → Neutral |
$21 → $7 |
|
Feb-28-19 | Reiterated |
BofA/Merrill |
Underperform |
$15 → $5 |
|
Feb-27-19 | Downgrade |
BofA/Merrill |
Neutral → Underperform |
$15 → $5 |
|
Jan-03-19 | Upgrade |
BofA/Merrill |
Underperform → Neutral |
|
|
Dec-03-18 | Initiated |
B. Riley FBR |
Buy |
$23 |
|
Nov-09-18 | Upgrade |
Wedbush |
Neutral → Outperform |
$19 |
|
May-24-18 | Downgrade |
Wedbush |
Outperform → Neutral |
$20 → $19 |
|
Apr-02-18 | Resumed |
Leerink Partners |
Outperform |
$19 |
|
Nov-15-17 | Resumed |
H.C. Wainwright |
Buy |
$23 |
|
Sep-15-17 | Initiated |
RBC Capital Mkts |
Outperform |
$14 |
|
Sep-08-16 | Reiterated |
H.C. Wainwright |
Buy |
$15 → $16 |
|
Aug-30-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
Aug-18-16 | Initiated |
H.C. Wainwright |
Buy |
$15 |
|
Jun-28-16 | Initiated |
Robert W. Baird |
Outperform |
$16 |
|
May-27-16 | Initiated |
Raymond James |
Outperform |
$13 |
|
Mar-16-16 | Reiterated |
Wedbush |
Outperform |
$38 → $16 |
|
Jan-06-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
|
 |
Dec-13-19 03:26PM | Hedge Funds Dropped The Ball On Karyopharm Therapeutics Inc (KPTI) Insider Monkey |
Dec-09-19 07:25AM | There's A Really Good Chance You Missed One Of The Year's Best ETFs Benzinga |
Dec-08-19 09:00AM | Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting GlobeNewswire |
Dec-07-19 09:00AM | Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting GlobeNewswire |
Dec-03-19 01:48PM | The Best-Performing ETF Has a Winning Strategy, But Just $29 Million Bloomberg |
Dec-02-19 04:05PM | Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
Nov-28-19 10:00AM | Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice Zacks |
Nov-09-19 10:25PM | Edited Transcript of KPTI earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents |
Nov-06-19 10:12AM | Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting GlobeNewswire |
08:52AM | Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks |
03:40AM | 3 Names Making the Case That Investing in Small Biotech Is Never Dull TheStreet.com |
Nov-05-19 06:53AM | The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga +6.38% |
Nov-04-19 11:28AM | Karyopharm exceeds analyst expectations for first cancer drug launch Reuters +6.22% |
08:25AM | Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates Zacks |
07:00AM | Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire |
Nov-03-19 10:51AM | The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga |
Nov-01-19 04:58PM | Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.18% |
Oct-31-19 01:52PM | Did Hedge Funds Drop The Ball On Karyopharm Therapeutics Inc (KPTI)? Insider Monkey |
Oct-30-19 03:30AM | SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders; Karyopharm Shareholders Urged to Contact the Firm ACCESSWIRE |
Oct-28-19 07:00AM | Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019 GlobeNewswire |
Oct-24-19 04:04PM | Shareholder Alert: Robbins Arroyo LLP Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders Business Wire |
Oct-21-19 11:42AM | If You Had Bought Karyopharm Therapeutics (NASDAQ:KPTI) Stock Five Years Ago, You'd Be Sitting On A 71% Loss, Today Simply Wall St. |
Oct-04-19 10:00PM | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire |
Oct-01-19 07:00AM | Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
Sep-23-19 12:30PM | CLASS ACTION UPDATE for MMM, KPTI and IFF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE -6.24% |
10:20AM | FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE |
09:19AM | CLASS ACTION UPDATE for MMM, KPTI, GTT and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
08:45AM | MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
Sep-22-19 10:50PM | KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI GlobeNewswire |
Sep-21-19 10:00AM | DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm Business Wire |
Sep-20-19 10:50PM | KARYOPHARM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI Business Wire -5.21% |
04:30PM | CLASS ACTION UPDATE for KPTI, CARB and OLLI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
03:00PM | INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 GlobeNewswire |
01:30PM | SHAREHOLDER ALERT: LB KPTI CARB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
01:00PM | FINAL SEPT. 23 DEADLINE: GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action KPTI GlobeNewswire |
10:30AM | KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm Newsfile |
10:25AM | UPCOMING DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE |
10:25AM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LB, KPTI and PS ACCESSWIRE |
10:04AM | MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
Sep-19-19 12:35PM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and TXT ACCESSWIRE |
11:15AM | KPTI DEADLINE: Pawar Law Group Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE |
10:00AM | FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 PR Newswire |
09:46AM | SHAREHOLDER ALERT: LB KPTI EGBN MDP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
06:25AM | CLASS ACTION DEADLINE UPDATE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines For Securities Violations: LB and KPTI ACCESSWIRE |
Sep-18-19 10:50PM | SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire |
08:55PM | SHAREHOLDER ALERT: KPTI NGHC MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
08:21PM | DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm PR Newswire |
11:45AM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LB, KPTI and GTT ACCESSWIRE |
10:49AM | UPCOMING DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE |
Sep-17-19 09:15PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, GTT and CAH ACCESSWIRE |
07:44PM | Pomerantz Law Firm Announces the Filing of a Class Action against Karyopharm Therapeutics Inc. and Certain Officers KPTI GlobeNewswire |
10:39AM | Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks |
09:58AM | CLASS ACTION UPDATE for NFLX, KPTI, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
Sep-16-19 10:50PM | SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire +7.43% |
02:05PM | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, GVA and NTAP ACCESSWIRE |
01:30PM | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire |
11:10AM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, NGHC and GTT ACCESSWIRE |
10:40AM | SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019 ACCESSWIRE |
10:30AM | Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. GlobeNewswire |
08:50AM | 7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
07:00AM | Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million GlobeNewswire |
Sep-15-19 11:05AM | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of OMCL, KPTI and NGHC ACCESSWIRE |
Sep-13-19 10:50PM | SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire |
06:30PM | Karyopharm Announces XPOVIO (Selinexor) Presentations at the 17th International Myeloma Workshop GlobeNewswire |
04:30PM | SHAREHOLDER ALERT: VNTR KPTI MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
03:30PM | Zhang Investor Law Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE |
03:00PM | Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire |
11:00AM | SHAREHOLDER ALERT: KPTI GTT SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
10:22AM | Class Action Alert - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
Sep-12-19 06:40PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, EGBN and MNK ACCESSWIRE |
05:05PM | ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action KPTI GlobeNewswire |
03:30PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, GVA and IFF ACCESSWIRE |
02:44PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI GlobeNewswire |
02:30PM | SEPTEMBER DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
09:32AM | SHAREHOLDER ALERT: OMCL KPTI NTAP TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
06:10AM | CLASS ACTION LAWSUIT UPDATE: Brodsky & Smith, LLC Is Investigating Securities Violations by the Following Companies: KPTI, IFF, PS ACCESSWIRE |
Sep-11-19 10:50PM | SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire |
06:05PM | CLASS ACTION UPDATE for NFLX, KPTI and GVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
05:00PM | FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
12:15PM | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of OMCL, KPTI and GVA ACCESSWIRE |
10:21AM | Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
09:24AM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, KPTI, PS and TXT GlobeNewswire |
06:35AM | CLASS ACTION UPDATE: Brodsky & Smith, LLC Is Investigating Securities Violations Related to the Following Companies: LB, KPTI and CURLF ACCESSWIRE |
Sep-10-19 07:30PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Omnicell, Ideanomics, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire +6.40% |
06:15PM | SEPTEMBER 23 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
04:55PM | SHAREHOLDER ALERT: KPTI GTT GVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
04:30PM | NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM KPTI GlobeNewswire |
12:35PM | CLASS ACTION UPDATE for LB, KPTI and IFF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
11:01AM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm GlobeNewswire |
09:38AM | CLASS ACTION UPDATE for OMCL, KPTI, CURLF and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
09:30AM | KPTI DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE |
Sep-09-19 10:50PM | SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire |
07:00PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OMCL, KPTI and VAL ACCESSWIRE |
10:45AM | CLASS ACTION UPDATE for VERB, LB and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
10:20AM | Class Action Reminder - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
09:40AM | UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
Sep-08-19 10:45AM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and ABMD ACCESSWIRE |
Sep-07-19 02:53PM | SEPTEMBER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
Sep-06-19 10:55PM | Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI ACCESSWIRE |
10:50PM | SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire |
|
|
|
 |
Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency. The company also reported positive results from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. Selinexor is also being evaluated in various other mid-and later-phase clinical trials in various cancer indications, including in multiple myeloma in a randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), as well as a therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL), in recurrent gliomas (KING), in endometrial cancer (SIENDO), and others. The company's SINE compounds also have biological activity in various models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. In addition, it has various investigational programs in clinical or preclinical development. The company was founded in 2008 and is headquartered in Newton, Massachusetts. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shacham Sharon | President & CSO | Dec 10 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Dec 11 05:21 PM | Kauffman Michael | Chief Executive Officer | Dec 10 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Dec 11 05:24 PM | Shacham Sharon | President & CSO | Dec 10 | Sale | 15.99 | 10,000 | 159,896 | 529,767 | Dec 11 05:21 PM | Kauffman Michael | Chief Executive Officer | Dec 10 | Sale | 15.99 | 10,000 | 159,896 | 529,767 | Dec 11 05:24 PM | Shacham Sharon | President & CSO | Dec 09 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Dec 11 05:21 PM | Kauffman Michael | Chief Executive Officer | Dec 09 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Dec 11 05:24 PM | Mirza Mansoor Raza | Director | Dec 09 | Option Exercise | 5.64 | 10,342 | 58,360 | 10,342 | Dec 11 05:26 PM | Mirza Mansoor Raza | Director | Dec 09 | Sale | 17.02 | 10,342 | 176,034 | 0 | Dec 11 05:26 PM | Kauffman Michael | Chief Executive Officer | Dec 09 | Sale | 17.02 | 10,000 | 170,210 | 731,134 | Dec 11 05:24 PM | Shacham Sharon | President & CSO | Dec 09 | Sale | 17.02 | 10,000 | 170,210 | 731,134 | Dec 11 05:21 PM | Primiano Christopher Brett | EVP, CBO, GC & Secretary | Dec 06 | Option Exercise | 8.47 | 10,000 | 84,650 | 16,653 | Dec 10 05:18 PM | Primiano Christopher Brett | EVP, CBO, GC & Secretary | Dec 06 | Sale | 17.45 | 13,000 | 226,908 | 3,653 | Dec 10 05:18 PM | Shacham Sharon | President & CSO | Nov 11 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Nov 12 04:34 PM | Kauffman Michael | Chief Executive Officer | Nov 11 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Nov 12 04:39 PM | Kauffman Michael | Chief Executive Officer | Nov 11 | Sale | 14.76 | 10,000 | 147,610 | 529,767 | Nov 12 04:39 PM | Shacham Sharon | President & CSO | Nov 11 | Sale | 14.76 | 10,000 | 147,610 | 529,767 | Nov 12 04:34 PM | Shacham Sharon | President & CSO | Nov 08 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Nov 12 04:34 PM | Kauffman Michael | Chief Executive Officer | Nov 08 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Nov 12 04:39 PM | Kauffman Michael | Chief Executive Officer | Nov 08 | Sale | 14.63 | 10,000 | 146,254 | 731,134 | Nov 12 04:39 PM | Shacham Sharon | President & CSO | Nov 08 | Sale | 14.63 | 10,000 | 146,254 | 731,134 | Nov 12 04:34 PM | Kauffman Michael | Chief Executive Officer | Nov 01 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Nov 05 04:08 PM | Kauffman Michael | Chief Executive Officer | Nov 01 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Nov 05 04:08 PM | Shacham Sharon | President & CSO | Nov 01 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Nov 05 04:10 PM | Shacham Sharon | President & CSO | Nov 01 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Nov 05 04:10 PM | Shacham Sharon | President & CSO | Nov 01 | Sale | 12.00 | 10,000 | 120,000 | 529,767 | Nov 05 04:10 PM | Shacham Sharon | President & CSO | Nov 01 | Sale | 12.00 | 10,000 | 120,000 | 731,134 | Nov 05 04:10 PM | Kauffman Michael | Chief Executive Officer | Nov 01 | Sale | 12.00 | 10,000 | 120,000 | 731,134 | Nov 05 04:08 PM | Kauffman Michael | Chief Executive Officer | Nov 01 | Sale | 12.00 | 10,000 | 120,000 | 529,767 | Nov 05 04:08 PM | Shacham Sharon | President & CSO | Sep 16 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Sep 17 04:54 PM | Shacham Sharon | President & CSO | Sep 16 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Sep 17 04:54 PM | Kauffman Michael | Chief Executive Officer | Sep 16 | Option Exercise | 4.75 | 10,000 | 47,520 | 741,134 | Sep 17 04:56 PM | Kauffman Michael | Chief Executive Officer | Sep 16 | Option Exercise | 4.75 | 10,000 | 47,520 | 539,767 | Sep 17 04:56 PM | Kauffman Michael | Chief Executive Officer | Sep 16 | Sale | 12.00 | 10,000 | 120,000 | 731,134 | Sep 17 04:56 PM | Kauffman Michael | Chief Executive Officer | Sep 16 | Sale | 12.00 | 10,000 | 120,000 | 529,767 | Sep 17 04:56 PM | Shacham Sharon | President & CSO | Sep 16 | Sale | 12.00 | 10,000 | 120,000 | 529,767 | Sep 17 04:54 PM | Shacham Sharon | President & CSO | Sep 16 | Sale | 12.00 | 10,000 | 120,000 | 731,134 | Sep 17 04:54 PM | Chione Ltd | 10% Owner | Feb 28 | Sale | 4.14 | 149,624 | 619,114 | 6,000,000 | Mar 04 08:28 PM | Chione Ltd | 10% Owner | Feb 27 | Sale | 4.51 | 558,243 | 2,515,834 | 6,149,624 | Feb 27 08:12 PM | Chione Ltd | 10% Owner | Feb 26 | Sale | 5.00 | 123,400 | 617,210 | 6,707,867 | Feb 27 08:12 PM | Chione Ltd | 10% Owner | Feb 25 | Sale | 4.99 | 800,000 | 3,994,880 | 6,831,267 | Feb 27 08:12 PM | Shacham Sharon | President & CSO | Jan 07 | Option Exercise | 0.03 | 12,500 | 413 | 743,634 | Jan 09 04:37 PM | Kauffman Michael | Chief Executive Officer | Jan 07 | Option Exercise | 0.03 | 12,500 | 413 | 743,634 | Jan 09 04:41 PM | Shacham Sharon | President & CSO | Jan 07 | Sale | 10.23 | 12,500 | 127,824 | 731,134 | Jan 09 04:37 PM | Kauffman Michael | Chief Executive Officer | Jan 07 | Sale | 10.23 | 12,500 | 127,824 | 731,134 | Jan 09 04:41 PM |
|
 |
|
 |
|